ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · IEX Real-Time Price · USD

18.77

-0.43 (-2.24%)

At close: Jul 19, 2024, 4:30 PM

18.90

+0.13 (0.69%)

Pre-market: Jul 22, 2024, 8:00 AM EDT

ArriVent BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	317.39	150.39	163.37
Cash & Cash Equivalents	317.39	150.39	163.37
Cash Growth	94.28%	-7.95%	-
Other Current Assets	10.09	9.58	19.25
Total Current Assets	327.48	159.97	182.62
Property, Plant & Equipment	0.25	0.29	0.14
Other Long-Term Assets	0.11	2.84	0.07
Total Long-Term Assets	0.36	3.13	0.21
Total Assets	327.84	163.1	182.83
Accounts Payable	4.1	4.53	3.09
Current Debt	0.15	0.14	0.13
Other Current Liabilities	5.73	6.95	5.14
Total Current Liabilities	9.98	11.62	8.36
Long-Term Debt	0.14	0.18	0.01
Total Long-Term Liabilities	0.14	0.18	0.01
Total Liabilities	10.12	11.8	8.37
Total Debt	0.29	0.32	0.14
Debt Growth	105.04%	128.06%	-
Retained Earnings	-175.26	-157.85	-88.51
Shareholders' Equity	317.72	-153.19	-85.11
Net Cash / Debt	317.11	150.07	163.23
Net Cash / Debt Growth	94.27%	-8.06%	-
Net Cash Per Share	-	70.10	127.82
Working Capital	317.5	148.34	174.26
Book Value Per Share	12.69	-71.55	-66.64

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).